In vitro analysis of anticoagulant compounds with a potential use as antithrombotic drugs, has been traditionally performed using techniques like spectrophotometry, turbidimetry, as well as electrochemical and clinical assays. Although, these techniques have some disadvantages such as: the inability to measure the total biological activity of thrombin, interferences and, sometimes, the quantitative determination of the inhibition ratio is not accurate.

In the present work, the conversion of fibrinogen to fibrin was monitored by molecular exclusion chromatography (SEC-HPLC) in three different reaction systems. An inhibition percentage of 43.19 ± 2.02% was obtained using heparin as an anticoagulant, in addition to the determination of the percentage of heparin bonded to thrombin.

This methodology has not been previously described and has high potential for the determination of anticoagulant capacity with higher precision, the determination of thrombin's total biological activity and the quantitative determination of the inhibition ratio.

传统上已经使用分光光度法，比浊法以及电化学和临床分析等技术对可能用作抗血栓药物的抗凝化合物进行了体外分析。尽管这些技术有一些缺点，例如：无法测量凝血酶的总生物活性，干扰，有时抑制率的定量测定是不准确的。

在目前的工作中，通过分子排阻色谱法（SEC-HPLC）在三种不同的反应系统中监测血纤蛋白原向血纤蛋白的转化。使用肝素作为抗凝剂，除测定与凝血酶结合的肝素的百分比外，还获得了43.19±2.02％的抑制百分比。

该方法以前没有被描述过，并且具有较高的潜力，可以更高精度地确定抗凝能力，确定凝血酶的总生物活性以及定量确定抑制率。